(Q37419829)

20 August 2017

1 reference

title

Recurrent Clostridium difficile infection: causality and therapeutic approaches (English)

1 reference

20 August 2017

main subject

Clostridium difficile

0 references

author name string

Stuart Johnson

series ordinal

1

1 reference

20 August 2017

publication date

1 March 2009

1 reference

International Journal of Antimicrobial Agents

20 August 2017

published in

1 reference

20 August 2017

volume

33 Suppl 1

1 reference

20 August 2017

page(s)

S33-6

1 reference

Clostridium difficile--associated diarrhea

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Nitazoxanide for the treatment of Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Ecological and evolutionary forces shaping microbial diversity in the human intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Colonization resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

12th C. L. Oakley lecture. Pathogenesis of Clostridium difficile infection of the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Relapse versus reinfection withClostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Colonization for the prevention of Clostridium difficile disease in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Serum antibody response to toxins A and B of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2809%2970014-7

7 January 2021

10.1016/S0924-8579(09)70014-7

Identifiers

DOI

1 reference

20 August 2017

1 reference